Oppenheimer


Nutanix Inc (NTNX) Named Top 2018 Pick At Oppenheimer

Nutanix gets another vote of confidence from Oppenheimer’s Ittai Kidron.

GoPro Inc (GPRO) Execution Is Not the Issue: Oppenheimer

Analyst has become more positive on GoPro’s new, impressive software; cautious only on sustainability.

Oppenheimer Sees Himax Technologies, Inc. (ADR) (HIMX) as an Overvalued Stock with Lost Growth Potential

Analyst warns that investors betting on Himax are naïve to bearish risks circling overhead.

DJI’s Spark Short Circuits Ambarella Inc (AMBA) Drone Revenue Leading to Weaker Outlook

Ambarella’s computer vision chips present enticing long-term possibilities, says Oppenheimer.

Palo Alto Networks Inc (PANW) New Product Development a Key to Continued Growth: Oppenheimer

Sales reorganization initiatives and improved execution levels are encouraging, says analyst.

Oppenheimer Comments on The Medicines Company (MDCO) Following FDA Approval for VABOMERE

The Medicines Company’s Vabomere – A Solid Option for CarbapenemResistant cUTIs: Oppenheimer

The Medicines Company (MDCO): Inclisiran Shows Momentum on Longer-Term Data, Oppenheimer Weighs in

Yesterday, at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, The Medicines Company (NASDAQ:MDCO) unveiled positive one-year data from the 501-patient …